Childhood Cancer: When Immunity Fails
"Unraveling the role of germline mutations and immunodeficiencies in pediatric cancers."
The diagnosis of cancer in a child inevitably raises questions about its origins, especially concerning hereditary or congenital factors. Parents often wonder if the disease stems from an inborn syndrome or a primary immunodeficiency (PID), particularly when there's a family history of early-onset malignancies.
Researchers have long explored the connection between genetic predispositions and cancer, guided by the 'multi-mutation' hypothesis and the 'cancer immunosurveillance' theory. The former, solidified by Nordling and Knudson, examines environmental genotoxic causes and inherent predispositions. The latter, championed by Burnet, posits that immune system defects can lead to cancer development. These theories help in understanding why some children are more susceptible to cancer.
Recent advances in genome sequencing and technology have pinpointed numerous genetic underpinnings of various diseases, offering targeted therapies. However, the causes of most childhood cancers remain elusive, suggesting multifaceted factors. In PIDs, both genetic defects and reduced immune surveillance may play a role. Maturation arrests, functional impairment of immune cells, and DNA-repair defects can predispose cells to malignant transformation. Simultaneously, weakened immune surveillance, chronic inflammation, and infections can further promote cancer development.
Tracking Pediatric Cancer Through National Registries
The National Childhood Cancer Registry (NCCR) collects data and publishes statistics to better understand the causes, outcomes, effective treatments, and late effects of cancer among children, adolescents, and young adults in the United States. Through NCCR*Explorer, researchers can access incidence and survival statistics for cancers in children and adolescent and young adults, ages 0-39, diagnosed from 2001 forward. The Childhood Cancer Clinical Data Commons serves as a primary source for deidentified, individual-level harmonized data describing the demographic and phenotypic characteristics of participants. These resources collectively provide comprehensive, well-documented, and trusted information for anyone seeking data and statistics related to pediatric cancers, with the CAC2 Fact Library team updating its listing annually to build awareness of diagnosis, treatment, remission, and survivorship realities.
Navigating Cancer in Immunocompromised Children
Primary immunodeficiencies (PIDs) are a heterogeneous group of inborn errors of immunity that are predetermined at birth but may evolve with age, leading to variable clinical and laboratory presentation. In contrast, secondary immunodeficiencies (SIDs) are acquired declines of immune cell counts and/or function. The management of cancers in children with underlying primary immunodeficiencies is a clinical challenge requiring the greatest circumspection in terms of accurate histological characterisation and understanding of oncogenic mechanisms. Contemporary diagnostic strategies enhance early identification and classification of these disorders, while emerging therapeutic approaches including gene editing technologies and novel biologic treatments offer potential advancements in care.
The Evolving Landscape of Primary Immunodeficiency and Cancer
Primary immunodeficiencies (PIDs) comprise a heterogeneous group of genetic disorders predisposing to frequent and severe infections, autoimmunity, and cancer. In recent years, the tendency to develop cancers has increased in parallel with improved life expectancy, largely due to effective immunoglobulin replacement and other supportive therapies. To be considered a primary immunodeficiency, the immune deficiency must be inborn, not caused by secondary factors such as other disease, drug treatment, or environmental exposure to toxins. The history of PIDs reveals a progression from initial discoveries to modern diagnostic breakthroughs, though understanding the causes of increased cancer risk and appropriate management strategies remains essential for patient care.
Why Primary Immunodeficiency Matters in Childhood Cancer
Malignancies are more prevalent and tend to manifest earlier in individuals with primary immunodeficiency (PID). Compared to the general population, the relative risk of cancer is higher in PID patients, with studies indicating that 4-25% develop malignancy during their lifetime. This heightened risk underscores the importance of understanding the interplay between immunodeficiency and cancer.
- Nijmegen breakage syndrome (NBS): Up to 42% of patients develop malignancies.
- Ataxia telangiectasia: Approximately 25% of patients are affected by malignancies.
Advances in Understanding Childhood Cancer and Immune Deficiency
Primary immunodeficiency disorders are a set of syndromes arising from defects in the immune system, with most diagnosed in young children and patients generally characterized by increased susceptibility to infections. In children, cancer remains the most common cause of disease-related mortality and is responsible for more deaths from infancy through adolescence than any other disease. Malignancies are observed more frequently in individuals with primary immunodeficiencies, highlighting the critical role of immune surveillance in cancer prevention. Recent advances focus on the clinical impact of infections in children with cancer or undergoing haematopoietic cell transplantation (HCT), as well as specific challenges in diagnostics and paediatric drug development, with Nature Immunology continuing to publish research articles exploring these primary immunodeficiency disorders.
Complexity and Rarity in Primary Immunodeficiency Disorders
The 2017 update of the "Primary Immunodeficiency Committee" of the "International Union of Immunological Societies" recognizes 344 genetic defects that define 354 distinct disorders of immunity in nine categories. Some of these monogenetic disorders are extremely rare and have been identified in single families only. While an association between primary immunodeficiency disorders and increased risk of cancer has been suggested since the 1970s, renewed attention has been given to this topic in the last decade, largely in light of the availability of new diagnostic and therapeutic tools. The complexity and rarity of these disorders present significant challenges for research and clinical management, requiring specialized expertise and collaborative approaches.
Immunotherapy vs. Conventional Treatment Approaches
Many primary immunodeficiencies (PIDs) are recognised as being associated with malignancies, particularly lymphoid malignancies, which represent the highest proportion of cancers occurring in conjunction with this underlying condition. The over-incidence of cancers observed alongside primary and secondary immunodeficiencies demonstrates the immune system's role in controlling the development of malignancy. When patients present with genetic errors of immunity, clinicians must often reflect on whether to manage antitumoral treatment conventionally or to take a more tailored approach. This comparison between immunotherapy and conventional treatments reveals important considerations for patient management in this complex clinical population.
Looking Ahead: Improving Outcomes for Children with PIDs and Cancer
The results suggest that primary immunodeficiencies (PIDs) do not directly facilitate tumor immune escape, but instead, malignancies in PID patients stem from inherent risks of cell transformation, chronic inflammation, and infections.
Integrating Knowledge Across Childhood Cancer and Immune Deficiency
The intersection of childhood cancer and immune deficiency represents a complex clinical landscape where understanding immune surveillance mechanisms is crucial. While significant progress has been made in identifying genetic defects underlying primary immunodeficiencies, translating this knowledge into effective treatments remains challenging. The relationship between immune system dysfunction and cancer development underscores the importance of comprehensive diagnostic approaches. Future efforts will need to balance the benefits of advanced therapies with the unique vulnerabilities of immunocompromised patients, requiring continued collaboration between researchers and clinicians to improve outcomes for children facing both conditions.
Trends and Projections in Pediatric Cancer
The incidence of childhood cancer has increased from 14.23 cases per 100,000 children in 1975–1979 to 18.89 in 2010–2019, with an average annual increase observed over this period. In 2024, a total of 14,910 children and adolescents ages 0 to 19 were estimated to be diagnosed with cancer and 1,590 to die from the disease according to the National Cancer Institute. For 2025, an estimated 14,690 children and adolescents will be diagnosed with cancer, compared to roughly two million cases in adults. The 5-year survival rate for all pediatric cancers combined has increased from 63 percent in the mid-1970s to 87 percent in 2015–2021, demonstrating significant improvements in treatment outcomes over recent decades.
Immune System Complexity and Disease Intersections
The immune system is composed of highly specialized cells, tissues, organs, and soluble factors that interact in a complex way to ensure an organism's immune defense. Systemic autoimmune diseases and primary immunodeficiencies/inborn errors of immunity (PIDs/IEIs) have traditionally been viewed as opposing immunological entities. However, growing genetic, immunological, and clinical evidence challenges this dichotomy, revealing a shared spectrum of immune dysregulation, genetic vulnerability, and convergent phenotypes. Advances in next-generation sequencing and other technologies are helping to elucidate these complex relationships, suggesting that the boundaries between these conditions may be more fluid than previously understood.
Living with Childhood Cancer and Immune Deficiency
The journey of children diagnosed with cancer and their families involves navigating complex medical decisions while coping with emotional and practical challenges. Access to specialized care and advanced treatments varies significantly across different regions and healthcare systems, creating disparities in outcomes. Support networks and patient advocacy groups play crucial roles in providing resources and information to affected families. The long-term effects of cancer treatment, including potential secondary immunodeficiencies, require ongoing monitoring and care, making comprehensive, family-centered approaches essential for improving quality of life.
Continued research into germline mutations and cancer predisposition in childhood is essential. As we uncover more of these genetic underpinnings, future therapies can target specific cancer pathways, potentially improving treatment outcomes.
Improved communication between hematologists, oncologists, and immunologists is critical to enhancing care and treatment for children with PIDs and cancer. By working together, these specialists can optimize prophylaxis, screening, and treatment strategies, ultimately improving the quality of life and survival rates for affected children.